I., Wist, J., Holmes, E., Bernal, A., Dou, B., Becker, G
The effects of tirzepatide on body weight control have also been confirmed in non-diabetic individuals in the SURMOUNT-1 study, where treatment with tirzepatide 1015 mg was associated with an average weight loss of approximately 20% at 72 weeks, exceeding 25% in one third of the patients
Youre supposed to rotate through them every week, anyway
All programs are described as cash-pay with no insurance billing
For orforglipron, participants initiated on higher doses and those on rapid titration schemes appeared to have higher discontinuation rates, providing insights into the optimisation process for the phase 3 trials
Clinical Effectiveness: SURMOUNT-1 Trial (Tirzepatide 15 mg): Duration: 72 weeks Participants: 2,539 adults with obesity Average Weight Loss: 22.5% of body weight 10 mg Dose: 21.4% weight loss 5 mg Dose: 15.0% weight loss Placebo: 2.4% weight loss 5% Weight Loss: 96% of participants 10% Weight Loss: 89% of participants 15% Weight Loss: 78% of participants 20% Weight Loss: 63% of participants This is the best weight loss result ever achieved with medication in clinical trials
